Tripos, Inc. and Servier have announced that they will work together to identify potential drugs. Servier identified and subsequently validated therapeutic compounds from Tripos' LeadQuest® compound collection.
Based on these results, Servier has chosen to partner with Tripos to further design and synthesize compounds for potential drug development. Tripos will employ its ChemSpace® and LeadHopping® proprietary technologies and integrated knowledge-driven chemistry processes to identify additional chemistries against the same targets.
Tripos' ChemSpace technology is used to identify similar but distinct chemical entities, while its LeadHopping technology helps scientists navigate the patent space.
"Servier has earned an impressive reputation for research, and to be chosen as their partner is an honor for our Tripos team," said Dr. Mark Allen, senior vice president and managing director of Tripos Discovery Research, Ltd.
He adds, "By applying our proprietary chemistry processes, Servier will be able to identify potential leads much sooner, therefore accelerating the research process. We hope the success we generate through this drug discovery project will lay the foundation for future Tripos and Servier partnerships and developments."